

ABSTRACT TOPIC LIST

(revised April 2018)

A: Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development

A1 Preclinical and translational aspects

A11 Preclinical aspects

- A111 Animal models and in-vitro studies
- A112 Tumor biology
- A113 Biology, benign disease

A12 Translational aspects

- A121 Cardiology
- A122 Neurology
- A123 Oncology
- A124 Therapy

A2 Radiopharmacy, radiochemistry, drug development

A21 Drug development

- A211 Radiopharmacokinetics and drug development
- A212 New biological targets and ligands

A22 Radiopharmacy

- A221 Radiopharmaceuticals - SPECT
- A222 Radiopharmaceuticals - PET
- A223 Radiopharmaceuticals – Therapy
- A224 Quality Control & Quality Assurance

A23 Radiochemistry

- A231 Radionuclide Production
- A232 Radiopharmaceutical Preparation

B: Technical aspects

B3 Instrumentation and data analysis

B31 Instrumentation

- B311 General aspects
- B312 Metric and intervention
- B313 SPECT and SPECT/CT
- B314 PET and PET/CT
- B315 PET/MR
- B316 Optical imaging
- B317 Imaging guided surgery

B32 Data analysis

- B321 Data analysis and management
- B322 Image reconstruction
- B323 Quality control, performance and standardization
- B324 Neurology: data analysis and quantification
- B325 Cardiology: data analysis and imaging systems

B4 Radioprotection and dosimetry

B41 Radioprotection

- B411 Radiation Exposure & Protection

B42 Dosimetry

- B421 Preclinical and clinical dosimetry and radiobiology

C: Clinical

C5 Diagnostic study

C51 Adult study

C511 Oncology study

C511-1 General oncology

- C511-1a Radioguided surgery
- C511-1b External beam radiation therapy planning
- C511-1c Therapy response assessment

C511-2 Organ-based oncology

- C511-2a Brain, malignant
- C511-2b Head and neck, malignant
- C511-2c Breast, malignant
- C511-2d Lung, malignant
- C511-2e Liver, Upper GI and Pancreatic (non-endocrine), malignant
- C511-2f Colorectal, malignant
- C511-2g Prostate, malignant
- C511-2h Other urological, malignant
- C511-2i Gynaecological, malignant
- C511-2j Hemato-oncology, malignant
- C511-2k Bone and soft tissues cancer
- C511-2l Melanoma, malignant
- C511-2m Endocrine, malignant
- C511-2n Thyroid, malignant

C512 Non oncology study

C512-1 Cardiovascular

- C512-1a Perfusion, metabolism and receptors
- C512-1b Plaque and vascular imaging

C512-2 Neurology

- C512-2a Dementia
- C512-2b Psychiatry
- C512-2c Neurodegeneration
- C512-2d Neurotransmission
- C512-2e Movement disorders
- C512-2f Other Neurology (i.e.: neuroinflammation, epilepsy, headache)

C512-3 Endocrinology

- C512-3a Endocrinology, benign
- C512-3b Thyroid, benign

C512-4 Musculoskeletal, infection and inflammation

- C512-4a Orthopedics, benign, no infection
- C512-4b Bone inflammation and infection
- C512-4c Soft tissue inflammation and infection (including cardiac, lung, brain, etc.)

C512-5 Other clinical studies

- C512-5a Pulmonology, benign
- C512-5b Gastroenterology, benign
- C512-5c Uro-nephrology, benign
- C512-5d Hematology, benign

C52 Paediatric study

- C521 Oncology
- C522 Benign

C6 Therapy study

C61 Thyroid treatment

- C611 Thyroid treatments, benign
- C612 Thyroid treatments, malignant

C62 Other treatments

- C621 mIBG and peptides therapy
- C622 Radioimmunotherapy
- C623 Bone metastases, pain palliation
- C624 Local radionuclide treatment